Although no targeted HER2 therapies are currently approved for HER2-low CRC or appendiceal cancers, agents such as trastuzumab deruxtecan have demonstrated clinical benefits in HER2-low breast cancer [45], suggesting potential future avenues for therapy. The gene discussed is ERBB2; the disease is breast cancer.